Dolby Laboratories (DLB) Financials

$74.91 +0.27 (+0.36%)

Closing price 03:59 PM Eastern

Extended Trading

$74.97 +0.06 (+0.09%)

As of 04:15 PM Eastern

Annual Income Statements for Dolby Laboratories

This table shows Dolby Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	9/27/2024	9/29/2023	9/30/2022	9/24/2021	9/25/2020	9/27/2019	9/28/2018	9/29/2017	9/30/2016	9/25/2015
Net Income / (Loss) Attributable to Common Shareholders	262	201	184	310	231	255	42	206	186	181
Consolidated Net Income / (Loss)	264	202	184	318	232	256	42	207	186	183
Net Income / (Loss) Continuing Operations	264	202	184	318	232	256	1,896	2,130	186	183
Total Pre-Tax Income	312	250	215	355	240	282	196	255	236	246
Total Operating Income	258	216	207	344	219	257	184	247	232	213
Total Gross Profit	1,133	1,147	1,112	1,151	1,015	1,081	1,854	1,923	917	876
Total Revenue	1,274	1,300	1,254	1,281	1,162	1,242	2,109	2,160	1,026	971
Operating Revenue	1,274	1,300	1,254	1,281	1,162	1,242	2,109	2,160	1,026	971
Total Cost of Revenue	140	153	141	130	146	161	255	237	109	95
Operating Cost of Revenue	140	153	141	130	146	161	255	237	109	95
Total Operating Expenses	875	931	906	807	797	824	-184	-247	685	663
Selling, General & Admin Expense	270	258	275	224	220	205	197	172	169	182
Marketing Expense	334	354	359	333	336	344	310	297	295	279
Research & Development Expense	264	272	261	254	239	238	237	233	220	201
Restructuring Charge	6.38	47	11	10	1.82	37	-0.45	13	1.23	-0.08
Total Other Income / (Expense), net	54	34	8.67	10	21	25	13	8.01	4.11	33
Interest Expense	-34	-28	-6.17	-3.01	0.19	0.17	0.20	0.13	0.13	0.18
Other Income / (Expense), net	20	6.21	2.50	7.11	8.43	0.48	-5.90	-1.44	-1.45	28
Income Tax Expense	48	48	31	37	8.10	27	154	48	50	63
Net Income / (Loss) Attributable to Noncontrolling Interest	2.49	0.99	-0.19	7.60	0.26	0.35	0.56	0.63	0.54	1.85
Basic Earnings per Share	$2.74	$2.10	$1.84	$3.07	$2.30	$2.51	$0.40	$2.03	$1.85	$1.77
Weighted Average Basic Shares Outstanding	95.54M	95.77M	99.99M	101.19M	100.56M	101.63M	103.38M	101.78M	100.72M	102.35M
Diluted Earnings per Share	$2.69	$2.05	$1.81	$2.97	$2.25	$2.44	$0.39	$2.00	$1.81	$1.75
Weighted Average Diluted Shares Outstanding	97.33M	97.73M	101.98M	104.62M	102.94M	104.57M	106.98M	103.29M	102.42M	103.86M
Weighted Average Basic & Diluted Shares Outstanding	95.44M	95.28M	95.96M	101.16M	100.35M	101.70M	104.40M	101.90M	100.50M	102.50M
Cash Dividends to Common per Share	$2.43	$2.19	$2.02	$0.88	$0.88	$1.55	$1.31	$1.14	$0.98	$0.82

This table shows Dolby Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	3/28/2025	12/27/2024	9/27/2024	6/28/2024	3/29/2024	12/29/2023	9/29/2023	6/30/2023	3/31/2023	12/30/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	92	68	59	38	98	67	9.19	16	96	79	28
Consolidated Net Income / (Loss)	92	68	59	40	98	68	9.91	16	96	79	28
Net Income / (Loss) Continuing Operations	92	68	59	40	98	68	9.91	16	96	79	28
Total Pre-Tax Income	120	86	60	50	122	81	9.03	24	117	100	31
Total Operating Income	108	80	46	37	109	66	-3.49	16	109	94	27
Total Gross Profit	334	316	271	253	326	284	255	257	335	300	241
Total Revenue	370	357	305	289	365	316	291	298	376	335	278
Operating Revenue	370	357	305	289	365	316	291	298	376	335	278
Total Cost of Revenue	36	41	34	36	39	32	36	42	41	34	37
Operating Cost of Revenue	36	41	34	36	39	32	36	42	41	34	37
Total Operating Expenses	226	236	224	216	217	217	259	241	226	206	214
Selling, General & Admin Expense	70	70	69	69	67	65	67	70	62	60	57
Marketing Expense	90	94	88	78	90	79	91	86	96	82	90
Research & Development Expense	62	67	69	66	62	67	70	69	68	64	62
Restructuring Charge	4.21	5.22	-1.29	4.08	-2.50	6.09	31	17	0.03	-0.24	4.58
Total Other Income / (Expense), net	12	6.17	13	13	13	15	13	7.82	8.06	5.89	3.87
Interest & Investment Income	3.56	2.65	-	9.44	8.60	9.19	-	7.20	6.81	4.80	-
Other Income / (Expense), net	8.93	3.53	6.53	3.94	4.18	5.43	3.25	0.62	1.25	1.10	0.67
Income Tax Expense	28	18	0.87	11	24	13	-0.88	7.35	21	21	3.22
Net Income / (Loss) Attributable to Noncontrolling Interest	0.43	0.25	0.30	1.21	0.38	0.60	0.72	0.01	0.19	0.07	0.00
Basic Earnings per Share	$0.95	$0.71	$0.62	$0.40	$1.02	$0.70	$0.10	$0.17	$1.00	$0.83	$0.29
Weighted Average Basic Shares Outstanding	96.33M	95.62M	95.54M	95.69M	95.72M	95.38M	95.77M	95.66M	95.82M	95.91M	99.99M
Diluted Earnings per Share	$0.94	$0.70	$0.59	$0.40	$1.01	$0.69	$0.08	$0.17	$0.98	$0.82	$0.29
Weighted Average Diluted Shares Outstanding	97.47M	97.15M	97.33M	96.96M	96.86M	97.44M	97.73M	97.46M	97.30M	97.05M	101.98M
Weighted Average Basic & Diluted Shares Outstanding	96.07M	96.38M	95.44M	95.35M	95.84M	95.58M	95.28M	95.64M	95.51M	95.82M	95.96M
Cash Dividends to Common per Share	$0.66	$0.66	$0.63	$0.60	$0.60	$0.60	$0.57	$0.54	$0.54	$0.54	$0.52

This table details how cash moves in and out of Dolby Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	9/27/2024	9/29/2023	9/30/2022	9/24/2021	9/25/2020	9/27/2019	9/28/2018	9/29/2017	9/30/2016	9/25/2015
Net Change in Cash & Equivalents	-240	190	-605	153	274	-120	291	115	-16	-37
Net Cash From Operating Activities	327	367	319	448	344	328	352	378	360	309
Net Cash From Continuing Operating Activities	327	367	319	448	344	328	352	378	360	309
Net Income / (Loss) Continuing Operations	264	202	184	318	232	256	42	207	186	183
Consolidated Net Income / (Loss)	264	202	184	318	232	256	42	207	186	183
Depreciation Expense	76	83	88	96	91	85	81	84	85	69
Amortization Expense	8.85	12	17	18	22	0.36	2.47	2.76	3.82	9.16
Non-Cash Adjustments To Reconcile Net Income	90	123	122	56	140	58	79	64	70	43
Changes in Operating Assets and Liabilities, net	-111	-52	-92	-41	-140	-72	147	20	15	4.38
Net Cash From Investing Activities	-286	54	-296	-45	134	-56	78	-158	-282	-204
Net Cash From Continuing Investing Activities	-286	54	-296	-45	134	-56	78	-158	-282	-204
Purchase of Property, Plant & Equipment	-30	-30	-48	-54	-66	-96	-73	-100	-101	-158
Acquisitions	-488	26	-38	-4.50	0.00	-15	-23	0.00	-121	-131
Purchase of Investments	-160	-173	-316	-67	-288	-265	-174	-290	-426	-393
Sale and/or Maturity of Investments	392	232	118	65	491	338	360	236	366	451
Other Investing Activities, net	0.00	0.00	-12	0.00	-2.64	-17	-13	-5.25	-0.71	-0.79
Net Cash From Financing Activities	-288	-237	-611	-253	-208	-385	-134	-107	-92	-139
Net Cash From Continuing Financing Activities	-289	-237	-611	-253	-208	-385	-134	-107	-92	-139
Repurchase of Common Equity	-199	-180	-567	-278	-197	-363	-173	-118	-114	-123
Payment of Dividends	-130	-104	-102	-97	-89	-79	-67	-59	-49	-47
Other Financing Activities, net	40	47	58	122	78	57	106	70	71	31
Effect of Exchange Rate Changes	6.64	5.12	-17	2.72	3.94	-5.82	-5.78	1.68	-1.40	-3.81
Cash Income Taxes Paid	63	61	40	71	53	60	61	57	55	52

This table details how cash moves in and out of Dolby Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	3/28/2025	12/27/2024	9/27/2024	6/28/2024	3/29/2024	12/29/2023	9/29/2023	6/30/2023	3/31/2023	12/30/2022	9/30/2022
Net Change in Cash & Equivalents	139	34	-201	-46	116	-109	19	106	62	3.11	-239
Net Cash From Operating Activities	175	107	116	21	181	8.41	85	121	105	56	51
Net Cash From Continuing Operating Activities	175	107	116	21	181	8.41	85	121	105	56	51
Net Income / (Loss) Continuing Operations	92	68	59	40	98	68	9.91	16	96	79	28
Consolidated Net Income / (Loss)	92	68	59	40	98	68	9.91	16	96	79	28
Depreciation Expense	22	22	21	18	18	18	21	21	21	19	19
Amortization Expense	2.89	2.84	2.69	2.07	1.90	2.19	2.45	3.05	3.31	3.29	3.82
Non-Cash Adjustments To Reconcile Net Income	13	7.84	24	23	49	-6.78	48	122	-36	-11	23
Changes in Operating Assets and Liabilities, net	46	5.67	8.90	-62	14	-72	3.17	-41	20	-34	-22
Net Cash From Investing Activities	26	-8.14	-261	-7.74	-18	0.63	-20	22	24	28	-41
Net Cash From Continuing Investing Activities	26	-8.14	-261	-7.74	-18	0.63	-20	22	24	28	-41
Purchase of Property, Plant & Equipment	-6.90	-6.78	-7.38	-7.61	-8.92	-6.10	-8.19	-7.41	-7.52	-7.22	-11
Sale and/or Maturity of Investments	16	0.00	247	43	59	42	38	46	39	108	33
Net Cash From Financing Activities	-65	-58	-60	-58	-44	-125	-43	-37	-67	-90	-242
Net Cash From Continuing Financing Activities	-65	-58	-61	-58	-45	-125	-43	-37	-67	-90	-242
Repurchase of Common Equity	-37	-47	-22	-36	-26	-115	-28	-27	-52	-74	-222
Payment of Dividends	-32	-32	-39	-32	-29	-30	-26	-26	-26	-26	-24
Other Financing Activities, net	3.97	22	-0.01	11	10	19	11	16	10	10	4.25
Cash Income Taxes Paid	33	11	12	12	27	12	21	13	15	13	10

This table presents Dolby Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	9/27/2024	9/29/2023	9/30/2022	9/24/2021	9/25/2020	9/27/2019	9/28/2018	9/29/2017	9/30/2016	9/25/2015
Total Assets	3,110	2,980	2,690	3,106	2,917	2,822	2,865	2,534	2,310	2,133
Total Current Assets	1,194	1,488	1,311	1,760	1,547	1,382	1,497	1,011	760	821
Cash & Equivalents	482	745	620	1,225	1,072	797	918	627	516	532
Restricted Cash	96	73	8.24	7.65	8.10	8.38	7.19	7.35	3.65	2.94
Accounts Receivable	315	262	244	233	180	189	166	74	76	102
Inventories, net	34	36	24	11	26	32	26	25	16	14
Prepaid Expenses	70	51	50	63	53	40	35	31	26	32
Other Current Assets	197	182	176	182	161	196	166	-	-	-
Plant, Property, & Equipment, net	479	482	513	534	542	537	514	485	444	403
Total Noncurrent Assets	1,436	1,010	865	811	828	903	855	1,037	1,107	909
Long-Term Investments	89	98	103	63	52	180	188	314	394	321
Goodwill	533	408	365	341	337	335	328	311	310	308
Intangible Assets	435	167	112	123	152	181	184	190	215	128
Noncurrent Deferred & Refundable Income Taxes	220	202	184	156	119	114	75	191	167	143
Other Noncurrent Operating Assets	160	135	102	128	168	93	80	31	21	9.46
Total Liabilities & Shareholders' Equity	3,110	2,980	2,690	3,106	2,917	2,822	2,865	2,534	2,310	2,133
Total Liabilities	623	608	439	501	479	509	495	390	331	317
Total Current Liabilities	418	422	278	316	267	307	285	246	213	210
Accounts Payable	17	21	14	18	13	15	22	14	18	21
Accrued Expenses	348	351	230	263	220	268	243	207	169	169
Current Deferred Revenue	32	32	19	18	-	-	-	23	24	19
Current Deferred & Payable Income Tax Liabilities	9.05	4.77	1.27	1.33	3.26	3.51	2.68	1.22	2.30	0.75
Other Current Liabilities	12	14	13	15	31	20	17	-	-	-
Total Noncurrent Liabilities	205	185	161	186	212	202	210	144	118	108
Noncurrent Deferred Revenue	35	40	23	24	-	-	-	36	35	31
Other Noncurrent Operating Liabilities	171	145	138	162	212	202	210	108	83	77
Total Equity & Noncontrolling Interests	2,487	2,372	2,251	2,604	2,438	2,313	2,371	2,144	1,979	1,816
Total Preferred & Common Equity	2,477	2,355	2,246	2,598	2,433	2,307	2,364	2,137	1,970	1,807
Total Common Equity	2,477	2,355	2,246	2,598	2,433	2,307	2,364	2,137	1,970	1,807
Common Stock	0.09	0.09	0.09	0.10	0.10	0.10	66	61	42	18
Retained Earnings	2,496	2,392	2,298	2,608	2,443	2,328	2,314	2,083	1,938	1,801
Accumulated Other Comprehensive Income / (Loss)	-19	-37	-52	-10	-11	-21	-16	-7.75	-10	-11
Noncontrolling Interest	9.73	17	4.84	6.25	5.76	5.68	6.57	7.10	8.48	8.94

This table presents Dolby Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/28/2025	12/27/2024	6/28/2024	3/29/2024	12/29/2023	6/30/2023	3/31/2023	12/30/2022	7/1/2022
Total Assets	3,229	3,159	2,974	3,045	2,936	3,008	2,836	2,749	2,920
Total Current Assets	1,389	1,286	1,469	1,552	1,451	1,469	1,463	1,349	1,505
Cash & Equivalents	627	521	742	710	657	765	688	626	859
Restricted Cash	124	91	37	115	52	34	4.98	5.32	8.35
Accounts Receivable	314	339	286	282	293	267	283	290	236
Inventories, net	35	32	35	36	38	32	30	26	24
Prepaid Expenses	60	82	51	50	54	54	54	53	50
Other Current Assets	230	221	191	243	218	193	275	216	170
Plant, Property, & Equipment, net	473	476	478	481	479	502	508	512	518
Total Noncurrent Assets	1,367	1,397	1,027	1,011	1,005	1,037	866	887	897
Long-Term Investments	74	86	118	128	93	98	101	124	107
Goodwill	525	520	408	409	410	426	370	369	368
Intangible Assets	412	421	145	152	160	177	99	106	119
Noncurrent Deferred & Refundable Income Taxes	223	227	220	208	207	210	204	192	184
Other Noncurrent Operating Assets	133	142	136	114	135	125	92	95	120
Total Liabilities & Shareholders' Equity	3,229	3,159	2,974	3,045	2,936	3,008	2,836	2,749	2,920
Total Liabilities	646	642	526	607	573	625	480	456	460
Total Current Liabilities	457	442	355	443	394	423	314	290	285
Accounts Payable	17	12	16	20	14	15	17	17	17
Accrued Expenses	376	361	281	363	327	347	247	230	229
Current Deferred Revenue	40	37	33	38	33	37	23	22	21
Current Deferred & Payable Income Tax Liabilities	13	21	12	8.38	6.19	11	14	7.18	3.85
Other Current Liabilities	11	11	13	14	13	14	13	13	14
Total Noncurrent Liabilities	189	200	172	164	179	202	166	166	175
Noncurrent Deferred Revenue	30	32	36	36	37	42	23	23	24
Other Noncurrent Operating Liabilities	159	167	136	128	142	161	143	143	151
Total Equity & Noncontrolling Interests	2,583	2,517	2,447	2,438	2,362	2,383	2,356	2,293	2,460
Total Preferred & Common Equity	2,574	2,508	2,433	2,421	2,346	2,366	2,351	2,288	2,454
Total Common Equity	2,574	2,508	2,433	2,421	2,346	2,366	2,351	2,288	2,454
Common Stock	0.10	0.10	0.09	0.09	0.09	0.09	0.10	0.10	0.10
Retained Earnings	2,602	2,543	2,463	2,450	2,367	2,397	2,378	2,319	2,485
Accumulated Other Comprehensive Income / (Loss)	-28	-36	-30	-29	-21	-31	-27	-32	-30
Noncontrolling Interest	9.35	9.06	15	17	16	16	5.21	4.95	5.16

This table displays calculated financial ratios and metrics derived from Dolby Laboratories' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	9/27/2024	9/29/2023	9/30/2022	9/24/2021	9/25/2020	9/27/2019	9/28/2018	9/29/2017	9/30/2016	9/25/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-2.00%	3.67%	-2.14%	10.28%	-6.43%	-41.13%	-2.37%	110.61%	5.68%	1.09%
EBITDA Growth	14.59%	0.79%	-32.53%	37.01%	-0.93%	31.25%	-21.46%	4.21%	-0.12%	-4.63%
EBIT Growth	25.43%	6.15%	-40.51%	54.73%	-11.80%	45.02%	-27.71%	6.66%	-4.59%	-11.43%
NOPAT Growth	25.59%	-1.42%	-42.84%	46.08%	-9.16%	488.55%	-80.29%	9.53%	15.21%	-23.17%
Net Income Growth	31.08%	9.65%	-42.14%	37.22%	-9.35%	503.96%	-79.57%	11.11%	1.73%	-12.21%
EPS Growth	31.22%	13.26%	-39.06%	32.00%	-7.79%	525.64%	-80.50%	10.50%	3.43%	-12.06%
Operating Cash Flow Growth	-10.85%	15.23%	-28.85%	30.22%	4.94%	-6.96%	-6.77%	4.92%	16.38%	-14.43%
Free Cash Flow Firm Growth	-251.40%	63.02%	-61.44%	85.74%	55.60%	211.74%	-147.00%	222.77%	311.83%	-116.99%
Invested Capital Growth	38.16%	-1.03%	4.83%	0.81%	4.19%	11.99%	13.93%	0.41%	14.88%	29.64%
Revenue Q/Q Growth	1.13%	0.96%	-0.54%	1.09%	-2.32%	-44.52%	-1.21%	101.45%	0.02%	0.60%
EBITDA Q/Q Growth	17.33%	-7.95%	-6.36%	-2.16%	2.82%	13.41%	-3.69%	-2.53%	-9.22%	2.45%
EBIT Q/Q Growth	23.58%	-11.21%	-6.52%	2.42%	-6.80%	17.59%	-5.26%	-2.85%	-12.86%	1.67%
NOPAT Q/Q Growth	27.40%	-12.48%	-8.91%	6.37%	-7.32%	8.97%	-0.81%	0.61%	-1.31%	-10.45%
Net Income Q/Q Growth	22.73%	-8.13%	-8.22%	5.74%	-6.82%	7.16%	0.56%	1.24%	-10.91%	0.30%
EPS Q/Q Growth	23.39%	-9.29%	-6.70%	5.69%	-7.02%	7.02%	0.00%	2.04%	-10.84%	0.00%
Operating Cash Flow Q/Q Growth	10.52%	10.11%	-15.51%	-0.64%	-4.93%	6.07%	9.75%	1.16%	-1.95%	-2.00%
Free Cash Flow Firm Q/Q Growth	-360.23%	12.85%	-29.45%	-0.98%	-12.09%	174.51%	-192.03%	11.60%	-4.78%	45.27%
Invested Capital Q/Q Growth	27.84%	-3.23%	0.17%	-2.20%	-3.82%	-4.39%	18.35%	-2.59%	-0.63%	-0.80%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.97%	88.26%	88.73%	89.85%	87.39%	87.04%	87.90%	89.03%	89.38%	90.23%
EBITDA Margin	28.48%	24.36%	25.06%	36.34%	29.25%	27.63%	12.39%	15.40%	31.13%	32.94%
Operating Margin	20.28%	16.60%	16.48%	26.88%	18.83%	20.71%	8.70%	11.44%	22.60%	21.97%
EBIT Margin	21.86%	17.08%	16.68%	27.43%	19.55%	20.74%	8.42%	11.37%	22.46%	24.87%
Profit (Net Income) Margin	20.75%	15.51%	14.67%	24.81%	19.94%	20.58%	2.01%	9.59%	18.17%	18.88%
Tax Burden Percent	84.59%	80.64%	85.42%	89.65%	96.62%	90.51%	21.54%	81.17%	79.02%	74.55%
Interest Burden Percent	112.24%	112.65%	102.95%	100.86%	105.52%	109.61%	110.57%	103.85%	102.41%	101.81%
Effective Tax Rate	15.41%	19.36%	14.58%	10.35%	3.38%	9.49%	78.46%	18.83%	20.98%	25.45%
Return on Invested Capital (ROIC)	13.93%	13.14%	13.57%	24.42%	17.13%	20.34%	3.90%	21.22%	20.76%	21.86%
ROIC Less NNEP Spread (ROIC-NNEP)	8.61%	10.34%	12.92%	23.70%	15.35%	18.43%	3.68%	20.64%	20.44%	19.54%
Return on Net Nonoperating Assets (RNNOA)	-3.05%	-4.42%	-6.00%	-11.81%	-7.38%	-9.43%	-2.03%	-11.17%	-10.93%	-11.53%
Return on Equity (ROE)	10.88%	8.72%	7.58%	12.61%	9.75%	10.91%	1.87%	10.05%	9.82%	10.33%
Cash Return on Invested Capital (CROIC)	-18.11%	14.17%	8.85%	23.61%	13.02%	9.03%	-9.12%	20.81%	6.91%	-3.96%
Operating Return on Assets (OROA)	9.14%	7.83%	7.22%	11.67%	7.92%	9.06%	6.58%	10.15%	10.37%	11.73%
Return on Assets (ROA)	8.68%	7.11%	6.35%	10.55%	8.07%	8.99%	1.57%	8.55%	8.39%	8.90%
Return on Common Equity (ROCE)	10.82%	8.68%	7.56%	12.58%	9.73%	10.88%	1.87%	10.01%	9.78%	10.24%
Return on Equity Simple (ROE_SIMPLE)	10.67%	8.56%	8.19%	12.23%	9.52%	11.07%	1.79%	9.69%	9.46%	10.14%
Net Operating Profit after Tax (NOPAT)	219	174	176	309	211	233	40	201	183	159
NOPAT Margin	17.16%	13.39%	14.08%	24.10%	18.19%	18.74%	1.87%	9.29%	17.86%	16.38%
Net Nonoperating Expense Percent (NNEP)	5.32%	2.80%	0.66%	0.72%	1.78%	1.91%	0.22%	0.58%	0.32%	2.32%
Cost of Revenue to Revenue	11.03%	11.74%	11.27%	10.15%	12.61%	12.96%	12.10%	10.97%	10.62%	9.77%
SG&A Expenses to Revenue	21.23%	19.89%	21.96%	17.50%	18.92%	16.54%	9.36%	7.95%	16.46%	18.77%
R&D to Revenue	20.70%	20.89%	20.83%	19.80%	20.58%	19.16%	11.23%	10.80%	21.41%	20.74%
Operating Expenses to Revenue	68.69%	71.66%	72.25%	62.97%	68.56%	66.34%	-8.70%	-11.44%	66.78%	68.26%
Earnings before Interest and Taxes (EBIT)	278	222	209	351	227	258	178	246	230	241
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	363	317	314	466	340	343	261	333	319	320
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.91	3.17	2.75	3.46	2.55	2.61	2.84	2.52	2.52	1.60
Price to Tangible Book Value (P/TBV)	4.78	4.20	3.50	4.21	3.20	3.36	3.63	3.29	3.44	2.11
Price to Revenue (P/Rev)	5.66	5.75	4.93	7.02	5.35	4.85	3.19	2.49	4.84	2.98
Price to Earnings (P/E)	27.53	37.22	33.59	28.99	26.85	23.62	160.96	26.07	26.74	15.93
Dividend Yield	1.59%	1.70%	1.58%	0.99%	1.42%	1.27%	0.99%	1.06%	0.98%	1.42%
Earnings Yield	3.63%	2.69%	2.98%	3.45%	3.72%	4.23%	0.62%	3.84%	3.74%	6.28%
Enterprise Value to Invested Capital (EV/IC)	3.60	4.88	3.96	6.04	4.00	4.08	5.04	4.43	4.18	2.32
Enterprise Value to Revenue (EV/Rev)	5.14	4.95	4.20	5.98	4.34	3.97	2.58	1.94	3.84	1.96
Enterprise Value to EBITDA (EV/EBITDA)	18.06	20.31	16.77	16.46	14.83	14.37	20.79	12.60	12.35	5.95
Enterprise Value to EBIT (EV/EBIT)	23.53	28.97	25.19	21.81	22.18	19.13	30.60	17.07	17.12	7.88
Enterprise Value to NOPAT (EV/NOPAT)	29.98	36.96	29.85	24.83	23.84	21.18	137.48	20.90	21.52	11.97
Enterprise Value to Operating Cash Flow (EV/OCF)	20.02	17.52	16.54	17.12	14.66	15.04	15.43	11.10	10.95	6.15
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	34.26	45.77	25.68	31.35	47.71	0.00	21.32	64.69	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.35	-0.43	-0.46	-0.50	-0.48	-0.51	-0.55	-0.54	-0.54	-0.59
Leverage Ratio	1.25	1.23	1.19	1.19	1.21	1.21	1.20	1.17	1.17	1.16
Compound Leverage Factor	1.41	1.38	1.23	1.20	1.27	1.33	1.32	1.22	1.20	1.18
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.39%	0.72%	0.21%	0.24%	0.24%	0.25%	0.28%	0.33%	0.43%	0.49%
Common Equity to Total Capital	99.61%	99.28%	99.79%	99.76%	99.76%	99.75%	99.72%	99.66%	99.57%	99.50%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.07	9.61	10.84	13.28	10.14	9.46	10.73	10.97	11.23	7.82
Noncontrolling Interest Sharing Ratio	0.55%	0.47%	0.23%	0.24%	0.24%	0.26%	0.31%	0.38%	0.46%	0.87%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.86	3.52	4.72	5.58	5.79	4.50	5.25	4.12	3.57	3.92
Quick Ratio	1.91	2.72	3.79	4.74	4.86	3.60	4.43	3.86	3.35	3.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-284	188	115	299	161	103	-92	197	61	-29
Operating Cash Flow to CapEx	1,090.59%	1,209.93%	664.70%	1,175.54%	518.26%	340.33%	483.70%	379.25%	357.34%	196.40%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	864.14	607.64	-466.91	1,548.78	487.51	-157.20
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	1,848.65	1,927.49	1,778.80	2,974.75	2,880.51	1,690.58
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	1,491.95	1,361.14	1,411.05	2,190.36	2,074.42	829.79
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.42	0.46	0.43	0.43	0.40	0.44	0.78	0.89	0.46	0.47
Accounts Receivable Turnover	4.41	5.14	5.27	6.21	6.29	6.99	17.59	28.91	11.57	10.34
Inventory Turnover	4.05	5.16	8.19	7.12	5.06	5.50	9.95	11.45	7.21	8.46
Fixed Asset Turnover	2.65	2.61	2.39	2.38	2.15	2.36	4.22	4.65	2.42	2.80
Accounts Payable Turnover	7.34	8.69	8.85	8.56	10.53	8.66	14.06	14.85	5.70	5.18
Days Sales Outstanding (DSO)	82.77	71.03	69.32	58.82	58.04	52.22	20.76	12.62	31.54	35.30
Days Inventory Outstanding (DIO)	90.08	70.78	44.56	51.25	72.11	66.41	36.67	31.88	50.62	43.13
Days Payable Outstanding (DPO)	49.76	41.98	41.25	42.66	34.67	42.13	25.96	24.57	64.06	70.46
Cash Conversion Cycle (CCC)	123.10	99.83	72.63	67.41	95.47	76.50	31.46	19.93	18.09	7.97
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,820	1,317	1,331	1,270	1,259	1,209	1,079	947	943	821
Invested Capital Turnover	0.81	0.98	0.96	1.01	0.94	1.09	2.08	2.29	1.16	1.33
Increase / (Decrease) in Invested Capital	503	-14	61	10	51	129	132	3.91	122	188
Enterprise Value (EV)	6,552	6,430	5,268	7,666	5,039	4,928	5,435	4,193	3,942	1,903
Market Capitalization	7,209	7,467	6,183	8,994	6,212	6,027	6,719	5,382	4,969	2,889
Book Value per Share	$25.98	$24.62	$23.00	$25.62	$24.18	$22.90	$22.81	$20.94	$19.52	$17.60
Tangible Book Value per Share	$15.83	$18.60	$18.11	$21.05	$19.32	$17.78	$17.87	$16.03	$14.32	$13.36
Total Capital	2,487	2,372	2,251	2,604	2,438	2,313	2,371	2,144	1,979	1,816
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-667	-1,055	-920	-1,335	-1,179	-1,104	-1,291	-1,196	-1,035	-995
Capital Expenditures (CapEx)	30	30	48	38	66	96	73	100	101	158
Debt-free, Cash-free Net Working Capital (DFCFNWC)	199	108	216	173	153	150	108	-116	-95	-62
Debt-free Net Working Capital (DFNWC)	777	1,066	1,033	1,445	1,280	1,075	1,211	766	547	612
Net Working Capital (NWC)	777	1,066	1,033	1,445	1,280	1,075	1,211	766	547	612
Net Nonoperating Expense (NNE)	-46	-28	-7.41	-9.07	-20	-23	-2.77	-6.50	-3.25	-24
Net Nonoperating Obligations (NNO)	-667	-1,055	-920	-1,335	-1,179	-1,104	-1,291	-1,196	-1,035	-995
Total Depreciation and Amortization (D&A)	84	95	105	114	113	85	84	87	89	78
Debt-free, Cash-free Net Working Capital to Revenue	15.61%	8.35%	17.21%	13.50%	13.18%	12.08%	5.12%	-5.39%	-9.24%	-6.41%
Debt-free Net Working Capital to Revenue	60.97%	81.98%	82.42%	112.76%	110.18%	86.56%	57.43%	35.44%	53.29%	63.00%
Net Working Capital to Revenue	60.97%	81.98%	82.42%	112.76%	110.18%	86.56%	57.43%	35.44%	53.29%	63.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.74	$2.10	$1.84	$3.07	$2.30	$2.51	$1.18	$1.98	$1.85	$1.77
Adjusted Weighted Average Basic Shares Outstanding	95.54M	95.77M	99.99M	101.19M	100.56M	101.63M	103.38M	101.78M	100.72M	102.35M
Adjusted Diluted Earnings per Share	$2.69	$2.05	$1.81	$2.97	$2.25	$2.44	$1.14	$1.95	$1.81	$1.75
Adjusted Weighted Average Diluted Shares Outstanding	97.33M	97.73M	101.98M	104.62M	102.94M	104.57M	106.98M	103.29M	102.42M	103.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$2.51	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	95.44M	95.28M	95.96M	101.16M	100.35M	100.20M	103.26M	102.29M	101.48M	100.85M
Normalized Net Operating Profit after Tax (NOPAT)	224	212	186	305	213	266	128	211	184	159
Normalized NOPAT Margin	17.58%	16.31%	14.80%	23.84%	18.34%	21.40%	6.08%	9.77%	17.95%	16.37%
Pre Tax Income Margin	24.53%	19.24%	17.17%	27.67%	20.63%	22.74%	9.31%	11.81%	23.00%	25.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	1,221.38	1,515.05	896.98	1,934.61	1,842.76	1,319.24
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	1,136.31	1,368.65	199.66	1,579.55	1,465.24	868.69
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	864.67	948.69	529.23	1,150.22	1,036.66	458.44
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	779.61	802.29	-168.09	795.16	659.15	7.89
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	49.06%	51.41%	55.19%	30.37%	38.37%	30.73%	158.79%	28.56%	26.08%	25.45%
Augmented Payout Ratio	124.37%	140.89%	363.47%	117.87%	123.34%	172.95%	566.81%	85.38%	87.50%	92.61%

This table displays calculated financial ratios and metrics derived from Dolby Laboratories' official financial filings.

Metric	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period end date	3/28/2025	12/27/2024	9/27/2024	6/28/2024	3/29/2024	12/29/2023	9/29/2023	6/30/2023	3/31/2023	12/30/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.38%	13.13%	4.90%	-3.20%	-3.02%	-5.78%	4.44%	3.03%	12.42%	-4.75%	-2.39%
EBITDA Growth	6.05%	18.42%	229.76%	50.34%	-1.45%	-22.03%	-53.96%	-46.36%	95.21%	-0.77%	-29.61%
EBIT Growth	3.13%	16.41%	21,508.91%	146.00%	2.42%	-24.73%	-100.89%	-65.57%	160.31%	4.82%	-34.43%
NOPAT Growth	-5.98%	14.13%	1,291.94%	164.25%	-1.56%	-25.95%	-115.78%	-69.88%	145.09%	-5.67%	-41.41%
Net Income Growth	-6.10%	0.72%	494.13%	141.73%	2.43%	-14.94%	-64.31%	-58.58%	162.56%	-0.70%	-37.24%
EPS Growth	-6.93%	1.45%	637.50%	135.29%	3.06%	-15.85%	-72.41%	-56.41%	172.22%	6.49%	-30.95%
Operating Cash Flow Growth	-3.59%	1,169.82%	36.65%	-82.45%	73.53%	-85.09%	65.69%	-29.82%	65.94%	78.13%	-53.26%
Free Cash Flow Firm Growth	-299.48%	-949.14%	-4,747.65%	-54.56%	82.14%	-16.00%	126.51%	-463.04%	697.47%	-11.08%	-218.68%
Invested Capital Growth	28.44%	28.11%	38.16%	4.58%	-4.59%	1.13%	-1.03%	2.45%	0.34%	2.01%	4.83%
Revenue Q/Q Growth	3.52%	17.12%	5.54%	-20.77%	15.51%	8.61%	-2.62%	-20.62%	12.23%	20.39%	-3.93%
EBITDA Q/Q Growth	29.94%	41.17%	25.90%	-54.08%	45.09%	293.12%	-42.60%	-69.90%	14.79%	132.12%	-33.12%
EBIT Q/Q Growth	39.91%	57.73%	29.85%	-64.01%	57.93%	29,106.48%	-101.49%	-85.01%	16.06%	242.70%	-42.23%
NOPAT Q/Q Growth	30.80%	38.33%	57.10%	-66.92%	58.77%	1,544.62%	-134.83%	-87.68%	19.44%	207.75%	-33.49%
Net Income Q/Q Growth	35.49%	15.64%	48.45%	-59.62%	45.33%	582.09%	-39.60%	-82.89%	20.69%	186.21%	-29.92%
EPS Q/Q Growth	34.29%	18.64%	47.50%	-60.40%	46.38%	762.50%	-52.94%	-82.65%	19.51%	182.76%	-25.64%
Operating Cash Flow Q/Q Growth	63.79%	-8.08%	446.32%	-88.28%	2,057.32%	-90.11%	-29.81%	15.87%	85.37%	9.91%	-70.27%
Free Cash Flow Firm Q/Q Growth	8.68%	26.48%	-1,273.92%	-121.63%	288.75%	302.38%	145.69%	-125.48%	79.27%	227.00%	-725.71%
Invested Capital Q/Q Growth	-3.31%	-0.04%	27.84%	3.95%	-3.55%	7.80%	-3.23%	-5.16%	2.22%	5.50%	0.17%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.30%	88.58%	88.85%	87.65%	89.36%	89.84%	87.76%	86.09%	89.08%	89.71%	86.64%
EBITDA Margin	38.19%	30.42%	25.24%	21.16%	36.50%	29.06%	8.03%	13.62%	35.92%	35.12%	18.22%
Operating Margin	29.16%	22.38%	15.21%	12.74%	29.89%	20.98%	-1.20%	5.34%	29.06%	28.09%	9.74%
EBIT Margin	31.58%	23.36%	17.35%	14.10%	31.04%	22.70%	-0.09%	5.55%	29.39%	28.42%	9.98%
Profit (Net Income) Margin	24.96%	19.07%	19.31%	13.73%	26.94%	21.42%	3.41%	5.50%	25.51%	23.72%	9.98%
Tax Burden Percent	76.70%	79.10%	98.55%	79.05%	80.67%	83.61%	109.69%	69.05%	81.75%	79.46%	89.62%
Interest Burden Percent	103.05%	103.17%	112.96%	123.18%	107.60%	112.82%	-3,657.09%	143.50%	106.16%	105.04%	111.52%
Effective Tax Rate	23.30%	20.90%	1.45%	20.95%	19.33%	16.39%	-9.69%	30.95%	18.25%	20.54%	10.38%
Return on Invested Capital (ROIC)	18.88%	14.37%	12.17%	9.11%	21.82%	15.91%	-1.29%	3.53%	21.20%	19.86%	8.42%
ROIC Less NNEP Spread (ROIC-NNEP)	17.86%	13.78%	10.64%	8.07%	20.78%	14.57%	-2.69%	3.03%	20.57%	19.43%	8.11%
Return on Net Nonoperating Assets (RNNOA)	-6.73%	-4.63%	-3.77%	-3.42%	-8.62%	-5.73%	1.15%	-1.35%	-8.69%	-8.48%	-3.77%
Return on Equity (ROE)	12.14%	9.74%	8.40%	5.69%	13.20%	10.18%	-0.15%	2.18%	12.51%	11.38%	4.65%
Cash Return on Invested Capital (CROIC)	-10.73%	-10.65%	-18.11%	7.84%	15.62%	9.82%	14.17%	12.36%	15.37%	10.39%	8.85%
Operating Return on Assets (OROA)	13.29%	10.08%	7.26%	5.94%	13.40%	10.23%	-0.04%	2.41%	12.74%	12.01%	4.32%
Return on Assets (ROA)	10.50%	8.23%	8.08%	5.78%	11.63%	9.65%	1.56%	2.39%	11.06%	10.03%	4.32%
Return on Common Equity (ROCE)	12.08%	9.69%	8.35%	5.65%	13.14%	10.13%	-0.15%	2.17%	12.48%	11.36%	4.64%
Return on Equity Simple (ROE_SIMPLE)	10.06%	10.56%	0.00%	8.85%	7.94%	8.09%	0.00%	9.28%	10.32%	8.01%	0.00%
Net Operating Profit after Tax (NOPAT)	83	63	46	29	88	55	-3.83	11	89	75	24
NOPAT Margin	22.36%	17.70%	14.99%	10.07%	24.11%	17.54%	-1.32%	3.69%	23.76%	22.32%	8.73%
Net Nonoperating Expense Percent (NNEP)	1.01%	0.60%	1.53%	1.03%	1.04%	1.33%	1.39%	0.50%	0.63%	0.43%	0.31%
Return On Investment Capital (ROIC_SIMPLE)	3.20%	2.51%	-	-	-	2.34%	-	-	-	-	-
Cost of Revenue to Revenue	9.70%	11.42%	11.15%	12.35%	10.64%	10.16%	12.24%	13.91%	10.92%	10.29%	13.36%
SG&A Expenses to Revenue	19.05%	19.63%	22.71%	23.99%	18.31%	20.65%	22.93%	23.45%	16.48%	17.91%	20.51%
R&D to Revenue	16.70%	18.67%	22.52%	22.68%	17.14%	21.24%	24.24%	23.02%	18.08%	19.24%	22.31%
Operating Expenses to Revenue	61.14%	66.20%	73.64%	74.92%	59.47%	68.86%	88.97%	80.75%	60.02%	61.62%	76.89%
Earnings before Interest and Taxes (EBIT)	117	83	53	41	113	72	-0.25	17	110	95	28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	141	109	77	61	133	92	23	41	135	118	51
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.99	2.99	2.91	3.11	3.28	3.46	3.17	3.32	3.41	2.89	2.75
Price to Tangible Book Value (P/TBV)	4.71	4.78	4.78	4.02	4.27	4.57	4.20	4.45	4.26	3.64	3.50
Price to Revenue (P/Rev)	5.83	5.70	5.66	6.00	6.26	6.34	5.75	6.09	6.26	5.34	4.93
Price to Earnings (P/E)	30.01	28.51	27.53	35.59	41.73	43.10	37.22	35.79	33.04	35.99	33.59
Dividend Yield	1.58%	1.57%	1.59%	1.48%	1.37%	1.31%	1.70%	1.29%	1.24%	1.48%	1.58%
Earnings Yield	3.33%	3.51%	3.63%	2.81%	2.40%	2.32%	2.69%	2.79%	3.03%	2.78%	2.98%
Enterprise Value to Invested Capital (EV/IC)	3.92	3.74	3.60	4.60	5.03	5.06	4.88	5.02	4.94	4.07	3.96
Enterprise Value to Revenue (EV/Rev)	5.22	5.17	5.14	5.20	5.43	5.61	4.95	5.31	5.55	4.62	4.20
Enterprise Value to EBITDA (EV/EBITDA)	17.76	17.91	18.06	21.19	23.87	24.73	20.31	19.89	18.71	18.26	16.77
Enterprise Value to EBIT (EV/EBIT)	23.45	23.44	23.53	29.08	34.27	36.23	28.97	27.36	25.20	26.79	25.19
Enterprise Value to NOPAT (EV/NOPAT)	31.07	30.00	29.98	38.20	45.01	46.55	36.96	34.41	31.52	33.23	29.85
Enterprise Value to Operating Cash Flow (EV/OCF)	16.43	15.98	20.02	22.13	17.41	22.53	17.52	20.52	18.43	16.66	16.54
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	60.01	31.47	51.86	34.26	41.14	32.22	39.59	45.77
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.38	-0.34	-0.35	-0.42	-0.41	-0.39	-0.43	-0.44	-0.42	-0.44	-0.46
Leverage Ratio	1.25	1.25	1.25	1.24	1.23	1.22	1.23	1.22	1.19	1.19	1.19
Compound Leverage Factor	1.29	1.29	1.42	1.53	1.32	1.38	-44.85	1.76	1.26	1.25	1.33
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.36%	0.36%	0.39%	0.60%	0.69%	0.70%	0.72%	0.69%	0.22%	0.22%	0.21%
Common Equity to Total Capital	99.64%	99.64%	99.61%	99.40%	99.31%	99.30%	99.28%	99.31%	99.78%	99.78%	99.79%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.16	8.96	8.83	10.70	9.96	10.57	9.36	9.51	12.25	10.89	10.62
Noncontrolling Interest Sharing Ratio	0.52%	0.52%	0.55%	0.64%	0.46%	0.46%	0.47%	0.45%	0.21%	0.20%	0.23%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.04	2.91	2.86	4.14	3.50	3.68	3.52	3.47	4.66	4.65	4.72
Quick Ratio	2.06	1.95	1.91	3.26	2.50	2.77	2.72	2.73	3.50	3.61	3.79
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-307	-336	-457	-33	154	40	9.83	-22	84	47	-37
Operating Cash Flow to CapEx	2,535.84%	1,575.14%	1,574.33%	279.31%	2,034.65%	137.88%	1,038.67%	1,634.01%	1,389.45%	781.42%	479.08%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.42	0.43	0.42	0.42	0.43	0.45	0.46	0.43	0.43	0.42	0.43
Accounts Receivable Turnover	4.43	4.16	4.41	4.56	4.49	4.39	5.14	5.12	5.01	4.66	5.27
Inventory Turnover	4.16	4.30	4.05	4.23	4.47	4.72	5.16	5.46	6.33	7.29	8.19
Fixed Asset Turnover	2.77	2.75	2.65	2.57	2.57	2.58	2.61	2.53	2.47	2.37	2.39
Accounts Payable Turnover	7.90	11.50	7.34	8.93	8.02	9.46	8.69	9.57	10.41	7.85	8.85
Days Sales Outstanding (DSO)	82.42	87.78	82.77	80.09	81.32	83.07	71.03	71.32	72.88	78.34	69.32
Days Inventory Outstanding (DIO)	87.83	84.88	90.08	86.22	81.62	77.39	70.78	66.87	57.68	50.06	44.56
Days Payable Outstanding (DPO)	46.18	31.73	49.76	40.87	45.53	38.59	41.98	38.13	35.05	46.50	41.25
Cash Conversion Cycle (CCC)	124.07	140.93	123.10	125.45	117.41	121.87	99.83	100.05	95.51	81.90	72.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,759	1,819	1,820	1,424	1,369	1,420	1,317	1,361	1,435	1,404	1,331
Invested Capital Turnover	0.84	0.81	0.81	0.90	0.90	0.91	0.98	0.96	0.89	0.89	0.96
Increase / (Decrease) in Invested Capital	389	399	503	62	-66	16	-14	33	4.86	28	61
Enterprise Value (EV)	6,887	6,801	6,552	6,552	6,893	7,188	6,430	6,840	7,094	5,718	5,268
Market Capitalization	7,701	7,490	7,209	7,561	7,944	8,114	7,467	7,845	8,009	6,602	6,183
Book Value per Share	$26.70	$26.28	$25.98	$25.39	$25.33	$24.60	$24.62	$24.78	$24.53	$23.84	$23.00
Tangible Book Value per Share	$16.98	$16.41	$15.83	$19.61	$19.46	$18.62	$18.60	$18.46	$19.64	$18.89	$18.11
Total Capital	2,583	2,517	2,487	2,447	2,438	2,362	2,372	2,383	2,356	2,293	2,251
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-824	-698	-667	-1,024	-1,068	-942	-1,055	-1,021	-921	-888	-920
Capital Expenditures (CapEx)	6.90	6.78	7.38	7.61	8.92	6.10	8.19	7.41	7.52	7.22	11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	181	232	199	208	169	208	108	123	329	295	216
Debt-free Net Working Capital (DFNWC)	932	844	777	1,114	1,109	1,057	1,066	1,046	1,149	1,059	1,033
Net Working Capital (NWC)	932	844	777	1,114	1,109	1,057	1,066	1,046	1,149	1,059	1,033
Net Nonoperating Expense (NNE)	-9.58	-4.88	-13	-11	-10	-12	-14	-5.40	-6.59	-4.68	-3.46
Net Nonoperating Obligations (NNO)	-824	-698	-667	-1,024	-1,068	-942	-1,055	-1,021	-921	-888	-920
Total Depreciation and Amortization (D&A)	24	25	24	20	20	20	24	24	25	22	23
Debt-free, Cash-free Net Working Capital to Revenue	13.74%	17.66%	15.61%	16.53%	13.29%	16.23%	8.35%	9.55%	25.71%	23.82%	17.21%
Debt-free Net Working Capital to Revenue	70.58%	64.17%	60.97%	88.46%	87.38%	82.57%	81.98%	81.28%	89.83%	85.60%	82.42%
Net Working Capital to Revenue	70.58%	64.17%	60.97%	88.46%	87.38%	82.57%	81.98%	81.28%	89.83%	85.60%	82.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.95	$0.71	$0.62	$0.40	$1.02	$0.70	$0.10	$0.17	$1.00	$0.83	$0.29
Adjusted Weighted Average Basic Shares Outstanding	96.33M	95.62M	95.54M	95.69M	95.72M	95.38M	95.77M	95.66M	95.82M	95.91M	99.99M
Adjusted Diluted Earnings per Share	$0.94	$0.70	$0.59	$0.40	$1.01	$0.69	$0.08	$0.17	$0.98	$0.82	$0.29
Adjusted Weighted Average Diluted Shares Outstanding	97.47M	97.15M	97.33M	96.96M	96.86M	97.44M	97.73M	97.46M	97.30M	97.05M	101.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	96.07M	96.38M	95.44M	95.35M	95.84M	95.58M	95.28M	95.64M	95.51M	95.82M	95.96M
Normalized Net Operating Profit after Tax (NOPAT)	86	67	44	32	86	60	19	23	89	75	28
Normalized NOPAT Margin	23.24%	18.86%	14.57%	11.18%	23.56%	19.16%	6.53%	7.55%	23.76%	22.27%	10.21%
Pre Tax Income Margin	32.54%	24.10%	19.60%	17.37%	33.40%	25.61%	3.11%	7.96%	31.20%	29.85%	11.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	52.43%	49.98%	49.06%	54.00%	57.25%	56.45%	51.41%	46.52%	41.78%	55.05%	55.19%
Augmented Payout Ratio	107.39%	99.81%	124.37%	149.17%	158.96%	172.68%	140.89%	217.51%	264.18%	368.04%	363.47%

Frequently Asked Questions About Dolby Laboratories' Financials

When does Dolby Laboratories's fiscal year end?

According to the most recent income statement we have on file, Dolby Laboratories' financial year ends in September. Their financial year 2024 ended on September 27, 2024.

How has Dolby Laboratories' net income changed over the last 9 years?

Dolby Laboratories' net income appears to be on an upward trend, with a most recent value of $264.32 million in 2024, rising from $183.24 million in 2015. The previous period was $201.64 million in 2023. Find out what analysts predict for Dolby Laboratories in the coming months.

What is Dolby Laboratories's operating income?

Dolby Laboratories's total operating income in 2024 was $258.33 million, based on the following breakdown:

Total Gross Profit: $1.13 billion
Total Operating Expenses: $874.90 million

How has Dolby Laboratories revenue changed over the last 9 years?

Over the last 9 years, Dolby Laboratories' total revenue changed from $970.64 million in 2015 to $1.27 billion in 2024, a change of 31.2%.

How much debt does Dolby Laboratories have?

Dolby Laboratories' total liabilities were at $623.04 million at the end of 2024, a 2.5% increase from 2023, and a 96.4% increase since 2015.

How much cash does Dolby Laboratories have?

In the past 9 years, Dolby Laboratories' cash and equivalents has ranged from $482.05 million in 2024 to $1.23 billion in 2021, and is currently $482.05 million as of their latest financial filing in 2024.

How has Dolby Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Dolby Laboratories' book value per share changed from 17.60 in 2015 to 25.98 in 2024, a change of 47.6%.

Related Companies

This page (NYSE:DLB) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dolby Laboratories (DLB) Financials

Frequently Asked Questions About Dolby Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dolby Laboratories (DLB) Financials

Annual Income Statements for Dolby Laboratories

Quarterly Income Statements for Dolby Laboratories

Annual Cash Flow Statements for Dolby Laboratories

Quarterly Cash Flow Statements for Dolby Laboratories

Annual Balance Sheets for Dolby Laboratories

Quarterly Balance Sheets for Dolby Laboratories

Annual Metrics And Ratios for Dolby Laboratories

Quarterly Metrics And Ratios for Dolby Laboratories

Frequently Asked Questions About Dolby Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools